Literature DB >> 28157430

Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Rajoshi Biswas1, Nicola A Hanania2, Ashutosh Sabharwal1.   

Abstract

BACKGROUND: The effectiveness of metered-dose inhalers (MDIs) in delivering medication to the lungs highly depends on its correct usage technique. Current guidelines state optimal technique for high lung deposition should include a slow inhalation (>5 seconds) at an inspiratory flow rate of 30 L/min and inhaler actuation at the start of inhalation. However, these recommendations were based on clinical studies using CFC (chlorofluorocarbon)-MDIs and in vitro studies of HFA (hydrofluoroalkane)-MDIs using idealized MDI techniques of uniform inhalation and actuation, disregarding the nonuniform techniques of actual patients.
METHODS: To better understand the effects of time-varying MDI usage parameters on lung deposition of aerosol delivered by an HFA-MDI, we conducted an in vitro study modeled on real-life variable inspiratory flow and actuation techniques recorded from 15 subjects with asthma/chronic obstructive pulmonary disease (COPD). We developed a model representing the time-varying inspiratory flow waveforms and actuation timings based on 43 MDI techniques recorded from patients. Furthermore, we constructed an in vitro experimental setup using a mouth-throat cast, programmable MDI actuator, and breath simulator to evaluate lung deposition for the MDI techniques derived from our model.
RESULTS: High inspiratory flow rates, 60-90 L/min, consistently resulted in high in vitro lung deposition (>40%) of aerosol (albuterol delivered from Ventolin HFA-MDI) compared to 30 L/min when MDI actuation occurred in the first half of inhalation. Also, positive coordination resulted in higher in vitro lung deposition compared with negative or zero coordination (actuating before or at the start of inspiration). Furthermore, variation in coordination affected lung deposition more significantly (23%) than flow rate or duration of inspiration (≤5%).
CONCLUSIONS: In an in vitro experimental model based on inhalation data from patients with asthma and COPD, we demonstrated that aerosol lung deposition emitted from Ventolin HFA-MDI is most optimal for MDI actuation in the first half of inspiration at high flow rates (60-90 L/min).

Entities:  

Keywords:  COPD; aerosol; asthma; inhaler technique; lung deposition; metered-dose inhaler

Mesh:

Substances:

Year:  2017        PMID: 28157430      PMCID: PMC5564031          DOI: 10.1089/jamp.2015.1278

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  28 in total

1.  What does it mean when a patient says, "my asthma medication is not working?".

Authors:  Bruce K Rubin
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 2.  Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma.

Authors:  Toby G D Capstick; Ian J Clifton
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

3.  Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.

Authors:  Omar S Usmani; Martyn F Biddiscombe; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-09-28       Impact factor: 21.405

4.  Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols.

Authors:  William L Hoye; Erik M Mogalian; Paul B Myrdal
Journal:  Am J Health Syst Pharm       Date:  2005-11-01       Impact factor: 2.637

5.  Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler.

Authors:  Chet L Leach; Patricia J Davidson; Bruce E Hasselquist; Robert J Boudreau
Journal:  J Aerosol Med       Date:  2005

6.  In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs.

Authors:  Farzin M Shemirani; Susan Hoe; David Lewis; Tanya Church; Reinhard Vehring; Warren H Finlay
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-10-24       Impact factor: 2.849

7.  Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways.

Authors:  P Worth Longest; Geng Tian; Xiang Li; Yoen-Ju Son; Michael Hindle
Journal:  Ann Biomed Eng       Date:  2012-07-21       Impact factor: 3.934

Review 8.  How should a pressurized beta-adrenergic bronchodilator be inhaled?

Authors:  S P Newman; D Pavia; S W Clarke
Journal:  Eur J Respir Dis       Date:  1981-02

9.  What the pulmonary specialist should know about the new inhalation therapies.

Authors:  B L Laube; H M Janssens; F H C de Jongh; S G Devadason; R Dhand; P Diot; M L Everard; I Horvath; P Navalesi; T Voshaar; H Chrystyn
Journal:  Eur Respir J       Date:  2011-02-10       Impact factor: 16.671

10.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols.

Authors:  S P Newman; D Pavia; N Garland; S W Clarke
Journal:  Eur J Respir Dis Suppl       Date:  1982
View more
  3 in total

1.  Lower Inspiratory Breathing Depth Enhances Pulmonary Delivery Efficiency of ProAir Sprays.

Authors:  Mohamed Talaat; Xiuhua April Si; Jinxiang Xi
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-03

2.  ATTACHED, DETACHED and WITHOUT inhaler technique coaching tools to optimize pMDI use competence, asthma control and quality-of-life in asthmatic adults.

Authors:  Wesam G Ammari; Nathir M Obeidat; Abed Rahman Anani; Reem J AlKalbani; Mark Sanders
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

3.  Characterization and comparison of Re-Du-Ning aerosol particles generated by different jet nebulizers.

Authors:  Yi Zhang; Brian Chi-Yan Cheng; Cui Li; Yonghua Tao; Chanjuan Yu; Xinyue Liu; Xiaoyan Gao; Gan Luo
Journal:  RSC Adv       Date:  2019-09-25       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.